Skip to main content
MAZE logo

MAZE · Maze Therapeutics, Inc. · Analyst Estimates

Track MAZE — free
$31.37 -1.06 (-3.27%) At close · Nov 20
Market Cap
$1.72B
Shares
54.68M
Volume · Nov 20 818.95K Avg daily vol (3M) 730.21K

Analyst Estimates

Compare analyst forecasts for Maze Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Pull consensus estimates through the analyst estimates API or MCP →

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians. An EPS figure names its accounting basis, GAAP or Non-GAAP, where the capture records one, and compares only with the company's EPS on that basis; without one, the basis is not recorded.

Captured 2026-11-18 22:36 UTC · Publication dates shown per estimate · 4 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-2.95
-2.86
-2.68
8
-2.73
-2.74
-2.73
-2.73
0
0
1
1
Revenue
USD
Publication date not stated
20.00M
20.00M
20.00M
13
— — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-4.36
-3.30
-2.31
11
-3.19
-3.22
-3.18
-3.18
0
0
1
1
Revenue
USD
Publication date not stated
0.00
8.11M
60.00M
12
— — — — — — — —
Key facts CIK 1842295 CUSIP 578784100 13F (30d) 158 filings 153 filers Visit website Investor relations